

# Ioannis Avgerinos

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8249801/ioannis-avgerinos-publications-by-year.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

15 papers	223 citations	7 h-index	14 g-index
16 ext. papers	415 ext. citations	6.3 avg, IF	3.49 L-index

#	Paper	IF	Citations
15	Sotagliflozin for patients with type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2022</b> , 24, 106-114	6.7	2
14	GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes Research and Clinical Practice</i> , <b>2021</b> , 174, 108737	7.4	12
13	Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 2116-2124	6.7	9
12	Ultra-rapid-acting insulins for adults with diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 2395-2401	6.7	1
11	GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials. <i>Diabetes Research and Clinical Practice</i> , <b>2021</b> , 177, 108921	7.4	3
10	Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 822-831	6.7	6
9	Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes. <i>Annals of Internal Medicine</i> , <b>2021</b> , 174, 141	8	
8	Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 1857-1868	6.7	14
7	Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 335-345	6.7	27
6	Patients' and Clinicians' Preferences on Outcomes and Medication Attributes for Type 2 Diabetes: a Mixed-Methods Study. <i>Journal of General Internal Medicine</i> , <b>2020</b> , 1	4	5
5	Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. <i>Annals of Internal Medicine</i> , <b>2020</b> , 173, 278-286	8	70
4	Intravenous Immunoglobulin for Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , <b>2019</b> , 34, 281-289	2.5	5
3	Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 188-193	6.7	20
2	Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2019</b> , 12, 2549-2557	3.4	4
1	Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 2255-2263	6.7	39